Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice

Neurochem Res. 2022 Sep;47(9):2773-2779. doi: 10.1007/s11064-022-03642-9. Epub 2022 Jun 8.

Abstract

Valproic acid (VPA) is a drug used for the treatment of epilepsy, seizures, migraines, and bipolar disorders. Cyclin-dependent kinase 5 (Cdk5) is a Ser/Thr kinase activated by p35 or p39 in neurons and plays a role in a variety of neuronal functions, including psychiatric behaviors. We previously reported that VPA suppressed Cdk5 activity by reducing the expression of p35 in cultured cortical neurons, leaving p39 unchanged. In this study, we asked for the role of Cdk5 in VPA-induced anxiety and depression behaviors. Wild-type (WT) mice displayed increased anxiety and depression after chronic administration of VPA for 14 days, when the expression of p35 was decreased. To clarify their relationship, we used p39 knockout (KO) mice, in which p35 is the only Cdk5 activator. When p39 KO mice were treated chronically with VPA, unexpectedly, they exhibited fewer anxiety and depression behaviors than WT mice. The effects were p39 cdk5r2 gene-dosage dependent. Together, these results indicate that Cdk5-p39 plays a specific role in VPA-induced anxiety and depression behaviors.

Keywords: Anxiety; Cdk5; Depression; Psychiatric behavior; Valproic acid; p39.

MeSH terms

  • Animals
  • Anticonvulsants* / adverse effects
  • Anticonvulsants* / therapeutic use
  • Antimanic Agents* / adverse effects
  • Antimanic Agents* / therapeutic use
  • Anxiety* / chemically induced
  • Anxiety* / genetics
  • Cytoskeletal Proteins* / genetics
  • Depression* / chemically induced
  • Depression* / genetics
  • Lipid-Linked Proteins* / genetics
  • Mice
  • Mice, Knockout
  • Valproic Acid* / adverse effects
  • Valproic Acid* / therapeutic use

Substances

  • Anticonvulsants
  • Antimanic Agents
  • Cdk5r2 protein, mouse
  • Cytoskeletal Proteins
  • Lipid-Linked Proteins
  • Valproic Acid